Camlin Fine Sciences [CAMLINFINE] vs Grauer & Weil [GRAUWEIL] Detailed Stock Comparison

Camlin Fine Sciences
NSE
Loading...

Grauer & Weil
BSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Camlin Fine Sciences wins in 8 metrics, Grauer & Weil wins in 10 metrics, with 0 ties. Grauer & Weil appears stronger overall.
View Metrics Details
Vital Metrics Comparison
Metric | Camlin Fine Sciences | Grauer & Weil | Better |
---|---|---|---|
P/E Ratio (TTM) | 81.82 | 27.77 | Grauer & Weil |
Price-to-Book Ratio | 4.88 | 4.65 | Grauer & Weil |
Debt-to-Equity Ratio | 77.88 | 1.26 | Grauer & Weil |
PEG Ratio | N/A | 38.69 | N/A |
EV/EBITDA | 24.32 | 20.47 | Grauer & Weil |
Profit Margin (TTM) | -8.34% | 13.85% | Grauer & Weil |
Operating Margin (TTM) | 9.38% | 7.46% | Camlin Fine Sciences |
EBITDA Margin (TTM) | 9.38% | 7.46% | Camlin Fine Sciences |
Return on Equity | 5.71% | 18.02% | Grauer & Weil |
Return on Assets (TTM) | 4.56% | 8.70% | Grauer & Weil |
Free Cash Flow (TTM) | $-157.24M | $999.80M | Grauer & Weil |
Dividend Yield | N/A | 1.05% | N/A |
1-Year Return | 116.83% | 9.60% | Camlin Fine Sciences |
Price-to-Sales Ratio (TTM) | 2.64 | 3.85 | Camlin Fine Sciences |
Enterprise Value | $49.87B | $38.42B | Camlin Fine Sciences |
EV/Revenue Ratio | 2.99 | 3.39 | Camlin Fine Sciences |
Gross Profit Margin (TTM) | 52.72% | 41.05% | Camlin Fine Sciences |
Revenue per Share (TTM) | $96 | $25 | Camlin Fine Sciences |
Earnings per Share (Diluted) | $2.86 | $3.47 | Grauer & Weil |
Beta (Stock Volatility) | 0.38 | 0.28 | Grauer & Weil |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Camlin Fine Sciences vs Grauer & Weil Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
Stock | 1D | 1W | 1M | 3M | 6M | YTD |
---|---|---|---|---|---|---|
Camlin Fine Sciences | -5.00% | -12.21% | -20.34% | 52.42% | 68.39% | 70.98% |
Grauer & Weil | -1.30% | -0.52% | -8.37% | 18.19% | 0.93% | -8.46% |
Long-term Returns
Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
---|---|---|---|---|---|---|
Camlin Fine Sciences | 116.83% | 102.90% | 172.43% | 156.57% | 161.22% | 161.22% |
Grauer & Weil | 9.60% | 47.21% | 147.69% | 405.77% | 1,019.05% | 755.68% |
Performance & Financial Health Analysis: Camlin Fine Sciences vs Grauer & Weil
Metric | CAMLINFINE | GRAUWEIL |
---|---|---|
Market Information | ||
Market Cap | ₹43.97B | ₹43.69B |
Market Cap Category | Small cap | Small cap |
10 Day Avg. Volume | 402,758 | 133,480 |
90 Day Avg. Volume | 319,854 | 191,775 |
Last Close | ₹226.20 | ₹95.10 |
52 Week Range | ₹95.59 - ₹333.30 | ₹78.00 - ₹120.00 |
% from 52W High | -32.13% | -20.75% |
All-Time High | ₹333.30 (Jun 26, 2025) | ₹204.80 (Feb 26, 2024) |
% from All-Time High | -32.13% | -53.56% |
Growth Metrics | ||
Quarterly Revenue Growth | 0.09% | 0.02% |
Quarterly Earnings Growth | 0.08% | -0.12% |
Financial Health | ||
Profit Margin (TTM) | -0.08% | 0.14% |
Operating Margin (TTM) | 0.09% | 0.07% |
Return on Equity (TTM) | 0.06% | 0.18% |
Debt to Equity (MRQ) | 77.88 | 1.26 |
Cash & Liquidity | ||
Book Value per Share (MRQ) | ₹47.98 | ₹20.72 |
Cash per Share (MRQ) | ₹7.56 | ₹11.87 |
Operating Cash Flow (TTM) | ₹267.23M | ₹1.44B |
Levered Free Cash Flow (TTM) | ₹149.51M | ₹927.08M |
Dividends | ||
Last 12-Month Dividend Yield | N/A | 1.05% |
Last 12-Month Dividend | ₹0.00 | ₹1.00 |
Valuation & Enterprise Metrics Analysis: Camlin Fine Sciences vs Grauer & Weil
Metric | CAMLINFINE | GRAUWEIL |
---|---|---|
Price Ratios | ||
P/E Ratio (TTM) | 81.82 | 27.77 |
Forward P/E | 15.49 | 38.69 |
PEG Ratio | N/A | 38.69 |
Price to Sales (TTM) | 2.64 | 3.85 |
Price to Book (MRQ) | 4.88 | 4.65 |
Market Capitalization | ||
Market Capitalization | ₹43.97B | ₹43.69B |
Enterprise Value | ₹49.87B | ₹38.42B |
Enterprise Value Metrics | ||
Enterprise to Revenue | 2.99 | 3.39 |
Enterprise to EBITDA | 24.32 | 20.47 |
Risk & Other Metrics | ||
Beta | 0.38 | 0.28 |
Book Value per Share (MRQ) | ₹47.98 | ₹20.72 |
Financial Statements Comparison: Camlin Fine Sciences vs Grauer & Weil
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
Metric (MRQ) | CAMLINFINE | GRAUWEIL |
---|---|---|
Revenue/Sales | ₹4.14B | ₹3.40B |
Cost of Goods Sold | ₹1.96B | ₹2.00B |
Gross Profit | ₹2.18B | ₹1.40B |
Research & Development | N/A | N/A |
Operating Income (EBIT) | ₹747.15M | ₹237.20M |
EBITDA | ₹931.49M | ₹417.40M |
Pre-Tax Income | ₹2.16B | ₹343.50M |
Income Tax | ₹79.52M | ₹86.10M |
Net Income (Profit) | ₹1.10M | ₹257.40M |
Balance Sheet & Liquidity Metrics (MRQ)
Metric (MRQ) | CAMLINFINE | GRAUWEIL |
---|---|---|
Cash & Equivalents | ₹1.04B | ₹1.08B |
Total Current Assets | ₹11.83B | ₹9.36B |
Total Current Liabilities | ₹8.46B | ₹2.97B |
Long-Term Debt | ₹2.93B | ₹37.30M |
Total Shareholders Equity | ₹8.75B | ₹9.39B |
Retained Earnings | N/A | N/A |
Property, Plant & Equipment | ₹6.44B | ₹2.47B |
Cash Flow Statement Comparison (MRQ)
Metric (MRQ) | CAMLINFINE | GRAUWEIL |
---|---|---|
Operating Cash Flow | N/A | N/A |
Capital Expenditures | N/A | N/A |
Free Cash Flow | N/A | N/A |
Debt Repayment | N/A | N/A |
Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
Metric | CAMLINFINE | GRAUWEIL |
---|---|---|
Shares Short | N/A | N/A |
Short Ratio | N/A | N/A |
Short % of Float | N/A | N/A |
Average Daily Volume (10 Day) | 402,758 | 133,480 |
Average Daily Volume (90 Day) | 319,854 | 191,775 |
Shares Outstanding | 187.92M | 453.41M |
Float Shares | 82.53M | 127.47M |
% Held by Insiders | 0.46% | 0.72% |
% Held by Institutions | 0.13% | 0.00% |
Dividend Analysis & Yield Comparison: Camlin Fine Sciences vs Grauer & Weil
Metric | CAMLINFINE | GRAUWEIL |
---|---|---|
Last 12-Month Dividend | ₹0.00 | ₹1.00 |
Last 12-Month Dividend Yield | N/A | 1.05% |
3-Year Avg Annual Dividend | ₹0.00 | ₹0.58 |
3-Year Avg Dividend Yield | N/A | 0.45% |
3-Year Total Dividends | ₹0.00 | ₹1.73 |
Ex-Dividend Date | N/A | Aug 06, 2025 |